Pfizer Lifts 2025 EPS Guidance to $3.22 After $17.6 B Q4 Revenue Beat
Pfizer posted Q4 2025 revenue of $17.6 billion and EPS of $0.66, exceeding consensus, and lifted its full-year 2025 EPS guidance to $3.22. The FDA granted Priority Review to its HYMPAVZI sBLA for hemophilia patients aged 6 and older, and Assetmark increased its stake by 193,859 shares to 2.43 million.
1. Q4 2025 Earnings and Guidance
Pfizer reported $17.6 billion in Q4 2025 revenue and EPS of $0.66, both ahead of internal forecasts. The company raised its full-year 2025 EPS guidance to $3.22 per share, reflecting confidence in core products beyond COVID-19.
2. Priority Review for HYMPAVZI
FDA granted Priority Review to Pfizer’s supplemental biologics license application for HYMPAVZI (marstacimab), aiming to extend prophylactic treatment to hemophilia A and B patients aged 6 and older and pediatric patients aged 6 to 11 without inhibitors.
3. Assetmark’s Position Increase
Assetmark Inc. boosted its holding by 193,859 shares, an 8.7% increase, bringing its total to 2.43 million Pfizer shares and signaling heightened institutional confidence in the company’s strategic outlook.